Acute Myeloid Leukemia: How Do We Measure Success?

Acute Myeloid Leukemia: How Do We Measure Success?

The development and approval of novel, effective therapies for acute myeloid leukemia (AML) has lagged behind other malignancies. Judging success of therapy with meaningful endpoints is critical to development of new treatments. Overall survival (OS) has typically been the parameter necessary for re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current hematologic malignancy reports 2016-12, Vol.11 (6), p.528-536
Hauptverfasser: Sasine, Joshua P., Schiller, Gary J.
Format: Artikel
Sprache:eng
Schlagworte:
Acute Myeloid Leukemias (H Erba
Antibodies, Monoclonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Disease-Free Survival
Geriatrics/Gerontology
Hematology
Humans
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - mortality
Medicine
Medicine & Public Health
Oncology
Quality of Life
Remission Induction
Section Editor
Survival Rate
Topical Collection on Acute Myeloid Leukemias
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The development and approval of novel, effective therapies for acute myeloid leukemia (AML) has lagged behind other malignancies. Judging success of therapy with meaningful endpoints is critical to development of new treatments. Overall survival (OS) has typically been the parameter necessary for regulatory approval of experimental therapy in AML. Herein, we discuss different strategies to define outcomes for patients with AML and their relative challenges.
ISSN:1558-8211
1558-822X
DOI:10.1007/s11899-016-0346-x